drugset

drugset / Trial / NCT01699061

Effect of Tivantinib on the QTC Interval in Cancer Subjects

NCT01699061 ↗

Phase 1 Completed 38 enrolled Daiichi Sankyo Medpace, Inc. · collab

Non-randomizedSingle-groupSingle-blindTreatment

Summary

The purpose of this study is to determine the effects of tivantinib on the QTc interval in patients with solid tumors

Timeline

Start: 2012-07
Primary completion: 2013-01
Completion: 2013-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tivantinib	Small molecule	360 mg	Oral

Indications